IDEAS home Printed from https://ideas.repec.org/a/pal/palcom/v7y2020i1d10.1057_s41599-020-00626-4.html
   My bibliography  Save this article

Game theoretic analysis of persons, the pharmaceutical industry, and donors in disease contraction and recovery

Author

Listed:
  • Kjell Hausken

    (University of Stavanger)

  • Mthuli Ncube

    (Quantum Global Research Lab Ltd)

Abstract

Disease contraction and recovery depend on complex interaction between persons potentially contracting and recovering from the disease, the pharmaceutical industry potentially developing drugs, and donors potentially subsidizing drug development and drug purchases. Instead of analyzing each of these three kinds of players separately, assuming the behavior of the other two kinds of players to be given, this article analyzes the three kinds of players holistically and how they mutually interact and react to each other. A five-period game between N persons and a pharmaceutical company is developed. Each person chooses safe or risky behavior, and whether or not to buy a drug. The objectives are to determine which strategies the N persons and the pharmaceutical company choose depending on the model parameters. The pharmaceutical company develops the drug if sufficiently many persons contract the disease and buy the drug. A donor chooses parametrically whether to subsidize drug development and drug purchases. Nature chooses probabilistically disease contraction, and recovery versus death with and without applying the drug. The methodological procedure is to solve the game with backward induction specifying the conditions for each of five outcomes ranging from safe behavior to risky behavior and buying the drug. The results in the form of five outcomes for a person are safe behavior, risky behavior and no disease contraction, disease contraction without drug availability, disease contraction with drug availability but without buying the drug, and disease contraction and buying the drug. These five outcomes are spread across two outcomes for the pharmaceutical company which are not to develop versus to develop the drug. The utility for the donor is specified for these two outcomes. A procedure for estimating the parameters is presented based on HIV/AIDS data. The results are discussed in terms of how various parameter combinations cause the five outcomes. An example illustrates the players’ strategic choices.

Suggested Citation

  • Kjell Hausken & Mthuli Ncube, 2020. "Game theoretic analysis of persons, the pharmaceutical industry, and donors in disease contraction and recovery," Palgrave Communications, Palgrave Macmillan, vol. 7(1), pages 1-17, December.
    • Handle: RePEc:pal:palcom:v:7:y:2020:i:1:d:10.1057_s41599-020-00626-4
    DOI: 10.1057/s41599-020-00626-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1057/s41599-020-00626-4
    File Function: Abstract
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1057/s41599-020-00626-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    2. Lilani Kumaranayake & Charlotte Watts, 2001. "Resource allocation and priority setting of HIV|AIDS interventions: addressing the generalized epidemic in sub-Saharan Africa," Journal of International Development, John Wiley & Sons, Ltd., vol. 13(4), pages 451-466.
    3. Michael Kremer & Christopher M. Snyder, 2015. "Preventives Versus Treatments," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 130(3), pages 1167-1239.
    4. Sabina S. Alistar & Margaret L. Brandeau, 2012. "Decision Making for HIV Prevention and Treatment Scale up," Medical Decision Making, , vol. 32(1), pages 105-117, January.
    5. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group, 2012. "HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making," PLOS Medicine, Public Library of Science, vol. 9(7), pages 1-8, July.
    6. John F. Moxnes & Kjell Hausken, 2012. "Mathematical modelling of acute virus influenza A infections," Mathematical and Computer Modelling of Dynamical Systems, Taylor & Francis Journals, vol. 18(5), pages 521-538, February.
    7. S.J. Goldie & Y. Yazdanpanah & E. Losina & M.C. Weinstein & X. Anglaret & R.P. Walensky & H.E. Hsu & A. Kimmel & C. Holmes & J.E. Kaplan & K.A. Freedberg, 2006. "Cost-effectiveness of HIV treatment in Resource-Poor Settings - The case of Côte d'Ivoire," Post-Print hal-00199992, HAL.
    8. David Canning, 2006. "The Economics of HIV/AIDS in Low-Income Countries: The Case for Prevention," Journal of Economic Perspectives, American Economic Association, vol. 20(3), pages 121-142, Summer.
    9. Hamed Mamani & Stephen E. Chick & David Simchi-Levi, 2013. "A Game-Theoretic Model of International Influenza Vaccination Coordination," Management Science, INFORMS, vol. 59(7), pages 1650-1670, July.
    10. Michael Kremer & Christopher M. Snyder, 2003. "Why Are Drugs More Profitable Than Vaccines?," NBER Working Papers 9833, National Bureau of Economic Research, Inc.
    11. Kjell Hausken & Mthuli Ncube, 2017. "Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS," Health Economics Review, Springer, vol. 7(1), pages 1-12, December.
    12. Kjell Hausken & Mthuli Ncube, 2018. "Policy makers, the international community and people living with HIV/AIDS: the need for new commitment mechanisms," International Journal of Public Policy, Inderscience Enterprises Ltd, vol. 14(3/4), pages 275-301.
    13. Till Bärnighausen & Joshua A Salomon & Nalinee Sangrujee, 2012. "HIV Treatment as Prevention: Issues in Economic Evaluation," PLOS Medicine, Public Library of Science, vol. 9(7), pages 1-5, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hausken, Kjell & Ncube, Mthuli, 2015. "Policy-Makers, the International Community and People Living with HIV: The Need for New Commitment Mechanisms," UiS Working Papers in Economics and Finance 2015/6, University of Stavanger.
    2. Kjell Hausken & Mthuli Ncube, 2017. "Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS," Health Economics Review, Springer, vol. 7(1), pages 1-12, December.
    3. Kjell Hausken & Mthuli Ncube, 2021. "Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation," Health Economics Review, Springer, vol. 11(1), pages 1-14, December.
    4. Jamsheed Shorish, 2007. "Welfare analysis of HIV/AIDS: Formulating and computing a continuous time overlapping generations policy model," Economics Discussion Paper Series 0709, Economics, The University of Manchester.
    5. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    6. Kremer, Michael & Snyder, Christopher, 2018. "Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global D," CEPR Discussion Papers 12751, C.E.P.R. Discussion Papers.
    7. Arzi Adbi & Chirantan Chatterjee & Matej Drev & Anant Mishra, 2019. "When the Big One Came: A Natural Experiment on Demand Shock and Market Structure in India's Influenza Vaccine Markets," Production and Operations Management, Production and Operations Management Society, vol. 28(4), pages 810-832, April.
    8. Snyder, Christopher M. & Hoyt, Kendall & Gouglas, Dimitrios, 2023. "An optimal mechanism to fund the development of vaccines against emerging epidemics," Journal of Health Economics, Elsevier, vol. 91(C).
    9. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    10. Kremer, Michael, 2018. "Worst-Case Bounds on R&D and Pricing Distortions: Theory and Disturbing Conclusions if Consumer Values Follow the World Income," CEPR Discussion Papers 13241, C.E.P.R. Discussion Papers.
    11. Michael Kremer & Christopher M. Snyder, 2018. "Worst-Case Bounds on R&D and Pricing Distortions: Theory with an Application Assuming Consumer Values Follow the World Income Distribution," NBER Working Papers 25119, National Bureau of Economic Research, Inc.
    12. Joseph P. Newhouse, 2021. "An Ounce of Prevention," Journal of Economic Perspectives, American Economic Association, vol. 35(2), pages 101-118, Spring.
    13. Anil Aswani & Zuo-Jun Max Shen & Auyon Siddiq, 2019. "Data-Driven Incentive Design in the Medicare Shared Savings Program," Operations Research, INFORMS, vol. 67(4), pages 1002-1026, July.
    14. Muhammad Rahies Khan & Amir Manzoor, 2021. "Application and Impact of New Technologies in the Supply Chain Management During COVID-19 Pandemic: A Systematic Literature Review," International Journal of Economics & Business Administration (IJEBA), International Journal of Economics & Business Administration (IJEBA), vol. 0(2), pages 277-292.
    15. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    16. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    17. Linus Nyiwul, 2021. "Epidemic Control and Resource Allocation: Approaches and Implications for the Management of COVID-19," Studies in Microeconomics, , vol. 9(2), pages 283-305, December.
    18. Ingrid V Bassett & Darshini Govindasamy & Alison S Erlwanger & Emily P Hyle & Katharina Kranzer & Nienke van Schaik & Farzad Noubary & A David Paltiel & Robin Wood & Rochelle P Walensky & Elena Losina, 2014. "Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-11, January.
    19. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
    20. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pal:palcom:v:7:y:2020:i:1:d:10.1057_s41599-020-00626-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: https://www.nature.com/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.